Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company’s subsidiary Kannaway® has received a Gold Globee® Award in the 2021 CEO Awards for Executive Achievement of the Year in the Consumer Products category.

Globee® Awards’ coveted annual CEO World Awards program encompasses the world’s best in leadership, innovation, organizational performance, new products and services, excellence studies, corporate social responsibility, and milestones from every major industry in the world. This annual awards program celebrates the individuals and teams who set industry benchmarks for excellence.

“We have been leaders in the CBD industry for more than a decade and have worked tirelessly to break down barriers to bring free access to non-psychoactive cannabis not only in the US, but also in Latin America, Europe and Asia,” said Kannaway® CEO Blake Schroeder. “While we are honored to receive this award, there is much work to be done and we look forward to continuing to innovate product offerings and become the world’s first truly global cannabis companies.”

Details about Globee® Awards’ 9th Annual 2021 CEO World Awards and the list of 2021 winners are available at https://globeeawards.com/ceo-world-awards/winners/. 

About Kannaway®

Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.

About Medical Marijuana, Inc.

We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led byKannaway® andHempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners includingAXIM® Biotechnologies, Inc. and Neuropathix. Medical Marijuana, Inc. was named a top CBD producer byCNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company's flagship productReal Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available atOTCMarkets.com or by visitingwww.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video,click here. 

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations Contact:

Kathryn Brown
Account Director
CMW Media
P. 858-264-6600
This email address is being protected from spambots. You need JavaScript enabled to view it. 
www.cmwmedia.com

Investor Relations Contact:

P. (858) 283-4016
This email address is being protected from spambots. You need JavaScript enabled to view it.